Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study
Mai Tarek, Ahmed A Ali, Reda Biomy, Khaled Abdelkawy, Eman El-Khateeb · 2026
Read Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study by Mai Tarek, Ahmed A Ali, Reda Biomy, Khaled Abdelkawy, Eman El-Khateeb (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13269781.txt.
Description
Mai Tarek and co-authors published a trial report in 2026 on setting doses of two blood pressure drugs for patients with liver cirrhosis, scarring that changes how drugs are handled. Computer models of the body in cirrhosis first predicted lower doses by disease stage. Forty-four patients then took model-guided doses for three months.
Model doses fell sharply with severity, for example one drug dropping from 25 milligrams to about 2 in severe disease. In mild and moderate patients, both drugs were well tolerated and lowered blood pressure and heart rate. Liver and kidney tests stayed stable. One drug improved flow through the liver more, though it also caused more mild side effects. The authors back model-guided dosing.
Catalog record
| CREATOR | Mai Tarek, Ahmed A Ali, Reda Biomy, Khaled Abdelkawy, Eman El-Khateeb |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71479 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |